Blood pressure variability — 15 years later
Blood pressure variability (BPV) has been studied for a long time, and recently important new information has been obtained about the prognostic value of BPV and the influence of antihypertensive therapy on it. There are three groups of VBP characteristics that are most important from a practical po...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2025-01-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/3136 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849227502441988096 |
|---|---|
| author | V. M. Gorbunov E. V. Platonova |
| author_facet | V. M. Gorbunov E. V. Platonova |
| author_sort | V. M. Gorbunov |
| collection | DOAJ |
| description | Blood pressure variability (BPV) has been studied for a long time, and recently important new information has been obtained about the prognostic value of BPV and the influence of antihypertensive therapy on it. There are three groups of VBP characteristics that are most important from a practical point of view: 24-hour BPV, BPV of average duration and visit-to-visit variability (VVV). VVV has attracted the attention of scientists in recent years. In a recent study in patients who participated in the ASCOT-BPLA cohort (mean follow-up 17.4 years) it was shown that 1) SBP VVV proved to be a strong predictor of cardiovascular complications (CVC), independent of mean BP (and possibly stronger than the latter) including in patients with well-controlled AH; 2) the CVC risk (including stroke and coronary events) remained significantly lower in the amlodipine treatment group. This finding seems particularly interesting in view of the fact that during such a long follow-up period many patients changed their treatment regimen; baseline values of office BP in both groups did not differ significantly. Thus, the independent prognostic value of VVV has received new convincing confirmation. Amlodipine may be the optimal drug for the treatment of patients with elevated BPV, but further studies are required to prove this point. |
| format | Article |
| id | doaj-art-6c55c3c8f33643bab3fd41edcde7f445 |
| institution | Kabale University |
| issn | 1819-6446 2225-3653 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj-art-6c55c3c8f33643bab3fd41edcde7f4452025-08-23T10:00:37ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532025-01-0120664565110.20996/1819-6446-2024-31362258Blood pressure variability — 15 years laterV. M. Gorbunov0E. V. Platonova1National Medical Research Center for Therapy and Preventive MedicineNational Medical Research Center for Therapy and Preventive MedicineBlood pressure variability (BPV) has been studied for a long time, and recently important new information has been obtained about the prognostic value of BPV and the influence of antihypertensive therapy on it. There are three groups of VBP characteristics that are most important from a practical point of view: 24-hour BPV, BPV of average duration and visit-to-visit variability (VVV). VVV has attracted the attention of scientists in recent years. In a recent study in patients who participated in the ASCOT-BPLA cohort (mean follow-up 17.4 years) it was shown that 1) SBP VVV proved to be a strong predictor of cardiovascular complications (CVC), independent of mean BP (and possibly stronger than the latter) including in patients with well-controlled AH; 2) the CVC risk (including stroke and coronary events) remained significantly lower in the amlodipine treatment group. This finding seems particularly interesting in view of the fact that during such a long follow-up period many patients changed their treatment regimen; baseline values of office BP in both groups did not differ significantly. Thus, the independent prognostic value of VVV has received new convincing confirmation. Amlodipine may be the optimal drug for the treatment of patients with elevated BPV, but further studies are required to prove this point.https://www.rpcardio.online/jour/article/view/3136arterial hypertensionblood pressure variabilityvisit-to-visit blood pressure variabilityambulatory blood pressure monitoringhome blood pressure monitoringantihypertensive therapy |
| spellingShingle | V. M. Gorbunov E. V. Platonova Blood pressure variability — 15 years later Рациональная фармакотерапия в кардиологии arterial hypertension blood pressure variability visit-to-visit blood pressure variability ambulatory blood pressure monitoring home blood pressure monitoring antihypertensive therapy |
| title | Blood pressure variability — 15 years later |
| title_full | Blood pressure variability — 15 years later |
| title_fullStr | Blood pressure variability — 15 years later |
| title_full_unstemmed | Blood pressure variability — 15 years later |
| title_short | Blood pressure variability — 15 years later |
| title_sort | blood pressure variability 15 years later |
| topic | arterial hypertension blood pressure variability visit-to-visit blood pressure variability ambulatory blood pressure monitoring home blood pressure monitoring antihypertensive therapy |
| url | https://www.rpcardio.online/jour/article/view/3136 |
| work_keys_str_mv | AT vmgorbunov bloodpressurevariability15yearslater AT evplatonova bloodpressurevariability15yearslater |